Guidelines and support
Please note that substances related to Basta´s information
requirements are included in the file.
DPHP CAS-number 53306-54-0
DINP CAS-number 68515-48-0, 28553-12-0
DIDP CAS-number 68515-49-1, 26761-40-0
DOTO, Dioctyltin oxide CAS-number 870-08-6
Products already registered containing CAS-number 870-08-6 may remain registered during the evaluation period.
The exemption is limited to 3 years, with the possibility of extension, and may be reassessed if contradictory scientific data are presented. The step C quality control is limited to evaluating that the supplier has sufficient scientific data to support an exemption according the Basta methodology, and should not be interpreted as an assessment if the substance has an endocrine disrupting potential or not.
Substances approved for exemption are allowed for use in products registered in the Basta system according to criterion 5, provided they fulfill all other Basta criteria. The substance name, CAS number and concentration (weight%) are stated and made publicly searchable at BastaOnline for all products affected. The products are marked with an red exclamation mark in the public search function.
Procedures for the assessment of endocrine disruptors in the BASTA system are based on a methodology described in the report “Guidance document for handling criteria for endocrine disruptors in the construction industry” developed by the IVL Swedish Environmental Research Institute and representatives from the construction industry.
B2369 Guidance Document Endocrine Disrupters
A transition period will be applied during the period 1/1 2020 to 1/7 2020 to adapt to the new criterion. The EDS database, which has so far been the basis for criterion 5, continues to apply until 1/7 2020, but thereafter the EDS database will only be included in the BASTA system as an information requirement.
A. Substances assessed as endocrine disruptors as defined by the EU *
B. Substances that are listed on three selected lists and where there are indications that the substances are endocrine disruptors or alternatively that they are being investigated within the EU.
C. The possibility of questioning the substances listed under B if there are scientifically robust arguments. Mandatory documentation requirements and approval process.
Figure 1. Decision tree for the management of endocrine disruptors.